<DOC>
	<DOCNO>NCT02460068</DOCNO>
	<brief_summary>This Phase 3 , open-label , triple arm study aim evaluate overall survival ( OS ) fotemustine versus combination ipilimumab fotemustine combination Ipilimumab nivolumab patient metastatic melanoma brain metastasis .</brief_summary>
	<brief_title>A Study Fotemustine ( FTM ) Vs FTM Ipilimumab ( IPI ) IPI Nivolumab Melanoma Brain Metastasis</brief_title>
	<detailed_description>Metastatic melanoma aggressive tumor associate poor prognosis . Brain metastasis develop nearly half MM pts 30 40 % subject , brain first site relapse . The limited activity available agent , along relative resistance radiotherapy poor CNS penetration chemotherapeutic agent , make one daunting problem oncology . There optimal systemic local therapy melanoma metastatic brain . Though MM pt brain metastasis exclude phase II-III trial ipilimumab , initial evidence suggest anti-CTLA-4 monoclonal antibody ipilimumab might active single-agent also clinical setting . Preliminary result NIBIT-M1 phase II trial suggest safety efficacy combination fotemustine plus ipilimumab MM pt w/o brain metastases.Recent data phase I study MM pt w/o brain metastasis show concurrent administration ipilimumab ( 3 mg/kg ) plus anti-PD1 mAb nivolumab ( 1 mg/kg ) induce objective response 53 % pt , tumor reduction ≥80 % 41 % pt , 82 % 1-year OS , acceptable safety profile.Based long-term follow-up NIBIT-M1 study , activity concurrent administration ipilimumab nivolumabthe NIBIT-M2 study explore efficacy combination ipilimumab fotemustine ipilimumab nivolumab versus fotemustine alone pts melanoma metastatic brain .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Willing able give write informed consent . Histologic diagnosis malignant melanoma ; Stage IV melanoma ; No prior therapy advanced ( unresectable Stage III Stage IV ) disease ; No previous systemic corticosteroid therapy within 7 day ; Prior adjuvant treatment IFN immunotherapy allow exception antiCTLA4 ; Presence asymptomatic brain metastasis : patient must measurable metastasis brain , define lesion accurately measure 2 dimension ≥ 0.5 cm ( maximum 2 cm ) brain MRI contrast ; Pts previously treat brain stereotactic radiotherapy ( SRT ) , wholebrain radiotherapy ( WBRT ) and/or surgery , must develop new measurable brain lesion ; Life expectancy ≥ 12 week ; ECOG performance status 0 1 ( see Appendix 2 ) ; Normal laboratory test require . Subjects must know BRAF V600E mutation status consent BRAF V600E mutation test per local institutional standard . Negative screening test HIV , Hepatitis B , Hepatitis C. Men woman , 18 year old.Women childbearing potential ( WOCBP ) must use appropriate method ( ) contraception . WOCBP use adequate method avoid pregnancy 23 week ( 30 day plus time require nivolumab undergo five halflives ) last dose investigational drug Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix ; Primary ocular mucosal melanoma . Medical History Concurrent Diseases : Symptomatic brain metastasis require immediate local intervention ( radiotherapy ( RT ) and/or surgery ) ; Autoimmune disease Any underlying medical condition , opinion investigator , make administration study drug hazardous obscure interpretation adverse event , condition associate frequent diarrhea . Prohibited Treatments and/or Therapies : Concomitant therapy anticancer agent ; immunosuppressive agent ; nononcology vaccine therapy use prevention infectious disease ( 1 month prior dose study drug ) ; surgery radiotherapy ; investigational anticancer therapy ; chronic use systemic corticosteroid Previous treatment investigational product , include cancer immunotherapy , within 30 day ; Prior treatment antiCTLA4 and/or , antiPD1/PDL1 fotemustine . Sex Reproductive Status : WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 8 week study ; Women pregnant breastfeeding ; Women positive pregnancy test enrollment prior investigational product administration ; Sexually active fertile men use effective birth control partner WOCBP . Other Prisoners subject involuntarily incarcerate ; Subjects compulsorily detain treatment either psychiatric physical illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>melanoma brain metastasis</keyword>
	<keyword>nivolumab</keyword>
	<keyword>ipilimumab</keyword>
</DOC>